JP Morgan Chase
CRBP icon

JP Morgan Chase’s Corbus Pharmaceuticals CRBP Stock Holding History

JP Morgan Chase’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,920
Closed -$173K – 6378
2021
Q1 		$173K Buy
+2,920
New +$192K ﹤0.01% 5204

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

JP Morgan Chase's CRBP Position: Q2 2026 in Review

JP Morgan Chase opened a new position in Corbus Pharmaceuticals (CRBP) in Q2 2026: 6,854 shares worth $61.5K. The stake represents ﹤0.01% of the portfolio and ranks #6341 among its holdings. This is a return to the name: JP Morgan Chase previously reported a position in CRBP as recently as Q2 2025.

JP Morgan Chase first reported a position in CRBP in Q2 2016 and has held it in 33 quarters since. The position peaked at $2.42M in Q1 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • JP Morgan Chase held 6,854 shares of Corbus Pharmaceuticals worth $61.5K as of Q2 2026.
  • Corbus Pharmaceuticals was a new JP Morgan Chase position in Q2 2026.
  • Corbus Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6341 holding.
  • JP Morgan Chase first reported a position in Corbus Pharmaceuticals in Q2 2016 and has held it in 33 quarters since.
  • JP Morgan Chase's Corbus Pharmaceuticals position peaked at $2.42M in Q1 2024.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.